Trial Profile
A Double-Blind, Randomized, Four-Period Crossover Study to Assess the Effects of Single Oral Dose Dapagliflozin Administration on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Volunteers Age 18 to 45 Years
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Moxifloxacin
- Indications Bacterial infections; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 05 Jun 2009 Results presented at ADA 2009.
- 23 Jun 2008 New trial record.